Navigation Links
Biotech adds Central American markets to Sucanon distribution
Date:10/25/2007

VANCOUVER, Oct. 25 /PRNewswire-FirstCall/ - Biotech Holdings (the "Company", OTC BB: BIOHF.OB) reports that it has signed an agreement, with a private company based in El Salvador for marketing and distribution of its Sucanon Type II diabetes drug in four Central American countries, Guatemala, Honduras, Nicaragua and El Salvador.

The four new markets targeted in connection with this agreement have a total population of approximately 33 million people, with an estimated 775,000 cases of Type II Diabetes in the region.

The Central American markets will be served by Sucanon deliveries from the Company's contract-packager, based in Mexico City. The distributor will co-ordinate its advertising in the Central American region with advertising arranged by Biotech's office in Mexico.

This release has been approved by the Board of Directors of Biotech Holdings.

Robert B. Rieveley, Pres.

On behalf of the Board of Directors

Phone: 604 295 1119

Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed. There is no assurance that regulatory approval will be obtained in any specific market nor any assurance that sales, once begun, will be material.

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or info@biotechltd.com; For background information on Biotech Holdings, or to receive news updates, see http://www.biotechltd.com


'/>"/>
SOURCE Biotech Holdings Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Finland and India to interact and cooperate in the filed of telemedicine and biotechnology
9. Vical Biotech and NIH jointly develops HIV vaccine
10. Biotechnology Initiatives Planned In Hyderabad
11. Biotech Osiris to go public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... American adults with chronic conditions reported skipping doses or not filling a prescription ... uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
(Date:2/22/2017)... PA (PRWEB) , ... February 22, 2017 , ... Sideline ... where the company met national TV host Tom Seay and his production crew. ... a favorite among equestrians around the world. Saddle Sidekicks will be featured on ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National Heart ... advocates, and individuals join together to increase recognition about the risks of heart ... , “Today we mark a nationwide movement to raise awareness about a disease ...
(Date:2/22/2017)... MADISON HEIGHTS, MICHIGAN (PRWEB) , ... February 22, ... ... news and analysis of issues related to spine practices, is featuring Michigan neurosurgeon ... Jagannathan is known as one of a small number of neurosurgeons in Michigan ...
(Date:2/22/2017)... ... 22, 2017 , ... Michael J. Hennessy Associates, Inc. (MJH ... technology professionals and other key stakeholders with an array of valuable resources, Healthcare ... 1, announced Michael J. Hennessy, Jr., president of MJH Associates. , In ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By ... ... is forecasted to grow at a CAGR of 5.33% during 2016-2021 ... of infectious diseases along with surging demand of digital thermometer. Apart ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... , Feb. 22, 2017 Kineta, ... development of novel immune modulating therapies, today announced ... a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust chronic ... pain models. The study also establishes the a9a10 ... treatment of chronic pain. The findings were reported ...
Breaking Medicine Technology: